We have located links that may give you full text access.
Changes of Early Sepsis Biomarker Presepsin Level during Hemodialysis: Influence of β 2 -Microglobulin Clearance of Dialysis Membrane: A Preliminary Study.
Kidney Diseases 2019 Februrary
Background: Although presepsin (P-SEP) is an early sepsis biomarker, sepsis is often suspected after starting hemodialysis (HD). To enhance the utility of P-SEP, we investigated whether pre-HD P-SEP levels could be predicted using the P-SEP levels from blood samples collected after starting HD.
Methods: We observed P-SEP level changes due to HD and dialyzer passage in HD patients using a dialysis membrane with a β2 -microglobulin (β2 -MG) clearance of either ≥50 mL/min (high-flux) or < 30 mL/min (intermediate-flux). We calculated the removal ratios for the elimination of P-SEP or the predicted pre-HD P-SEP levels based on the correction of hemoconcentration.
Results: The P-SEP levels significantly decreased at 4 h after starting HD ( n = 8) using membranes with a β2 -MG clearance ≥50 mL/min; the removal ratios at 2 and 4 h were 42.8 ± 7.9% and 58.8 ± 18.4%, respectively. In contrast, the P-SEP levels did not decrease during the passage of dialyzer in 2 patients with a β2 -MG clearance < 30 mL/min, and the P-SEP levels increased during HD in all patients ( n = 10, including the abovementioned 2 patients) with a β2 -MG clearance < 30 mL/min. The predicted pre-HD P-SEP levels ( y ) were strongly correlated with the actually measured pre-HD P-SEP levels ( x ) ( R 2 = 0.9562) using the regression equation: y = 1.0987 x .
Conclusion: The levels of P-SEP with a molecular weight near that of β2 -MG decreased similarly to those of β2 -MG during HD using membranes with a β2 -MG clearance ≥50 mL/min. On the contrary, the levels of P-SEP rather increased during HD with a β2 -MG clearance < 30 mL/min, suggesting that P-SEP appeared not to be eliminated. Furthermore, the pre-HD P-SEP levels might be predictable by the correction of hemoconcentration using even blood samples collected after starting HD with a β2 -MG clearance < 30 mL/min.
Methods: We observed P-SEP level changes due to HD and dialyzer passage in HD patients using a dialysis membrane with a β2 -microglobulin (β2 -MG) clearance of either ≥50 mL/min (high-flux) or < 30 mL/min (intermediate-flux). We calculated the removal ratios for the elimination of P-SEP or the predicted pre-HD P-SEP levels based on the correction of hemoconcentration.
Results: The P-SEP levels significantly decreased at 4 h after starting HD ( n = 8) using membranes with a β2 -MG clearance ≥50 mL/min; the removal ratios at 2 and 4 h were 42.8 ± 7.9% and 58.8 ± 18.4%, respectively. In contrast, the P-SEP levels did not decrease during the passage of dialyzer in 2 patients with a β2 -MG clearance < 30 mL/min, and the P-SEP levels increased during HD in all patients ( n = 10, including the abovementioned 2 patients) with a β2 -MG clearance < 30 mL/min. The predicted pre-HD P-SEP levels ( y ) were strongly correlated with the actually measured pre-HD P-SEP levels ( x ) ( R 2 = 0.9562) using the regression equation: y = 1.0987 x .
Conclusion: The levels of P-SEP with a molecular weight near that of β2 -MG decreased similarly to those of β2 -MG during HD using membranes with a β2 -MG clearance ≥50 mL/min. On the contrary, the levels of P-SEP rather increased during HD with a β2 -MG clearance < 30 mL/min, suggesting that P-SEP appeared not to be eliminated. Furthermore, the pre-HD P-SEP levels might be predictable by the correction of hemoconcentration using even blood samples collected after starting HD with a β2 -MG clearance < 30 mL/min.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
The Effect of Albumin Administration in Critically Ill Patients: A Retrospective Single-Center Analysis.Critical Care Medicine 2024 Februrary 8
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app